Genomic reiterated at market outperform by JMP

JMP Securities analyst Charles C. Duncan reiterated Genomic Health, Inc. at market outperform and a $19 price target as the company's second-quarter results show positive Oncotype DX growth. The company's results beat the analyst's and consensus estimates on both top and bottom lines. JMP raised its full-year 2006 revenue expectations to $26.0 million, from $22.2 million, and decreased its projected net loss in 2006 to $1.24 per share, from $1.48. Shares of the Redwood City, Calif.-based biotechnology company were up $1.75, or 16.11%, at $12.61, on volume of 688,288 shares versus the three-month running average of 111,822 shares. (Nasdaq: GHDX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.